Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates

Company Performance - Co-Diagnostics, Inc. reported a quarterly loss of $0.36 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.34, but an improvement from a loss of $0.50 per share a year ago, indicating a year-over-year improvement in loss figures [1] - The company posted revenues of $0.15 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 60.79%, and a significant decline from year-ago revenues of $3.56 million [2] - Over the last four quarters, Co-Diagnostics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Co-Diagnostics shares have declined approximately 44.5% since the beginning of the year, contrasting with the S&P 500's decline of 2.9%, indicating significant underperformance in the market [3] - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $0.4 million, and for the current fiscal year, it is -$1.17 on revenues of $1.5 million [7] Industry Outlook - The Medical Services industry, to which Co-Diagnostics belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a relatively strong position within the market [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Co-Diagnostics' stock performance [5]